Status:
UNKNOWN
Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis
Lead Sponsor:
Temple University
Collaborating Sponsors:
Allergan
Conditions:
Renal Failure
Bacterial Infections
Eligibility:
All Genders
18+ years
Brief Summary
The study's primary objective is to determine plasma and dialysis fluid concentrations in patients prescribed ceftazidime-avibactam as the standard treatment for their infection and requiring continuo...
Eligibility Criteria
Inclusion
- Adults \> 18 years of age
- Patients requiring continuous renal replacement therapy (CRRT) due to acute or chronic renal failure
- documented or suspected infection requiring a prescription for ceftazidime-avibactam
Exclusion
- Patients on CRRT \< 24 hours
- Patients on ceftazidime-avibactam \< 24 hours
- Patients unable to remain on CRRT for 32 hours continuously without clotting
Key Trial Info
Start Date :
March 13 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 21 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03243864
Start Date
March 13 2017
End Date
October 21 2020
Last Update
April 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140